The interdisciplinary medicalengineering innovation team, comprised of professors, associate professors, assistant professors, postdoctoral fellows, and graduate students, is focused on cell diagnostic and therapeutic biochips based on the group's proprietary technology—Nano Electroporation (NEP). The team aims to develop customized, precise, efficient, and safe drug delivery and detection systems for the treatment of major clinical diseases, such as cancer, neurodegenerative diseases, and organ injury repair.

 Supported by grants from the National Natural Science Foundation of China (Outstanding Youth, General, and Youth Programs), the Ministry of Education's Changjiang Scholars Program, the Central Organization Department's High-Level Talent Program, and the National Key Research and Development Program, the team has published over 100 SCI papers, 75 of which have an impact factor greater than 10, including in journals such as Nature Nanotechnology, Nature Photonics, Nature Electronics, PNAS, Nature Communications, and Science Advances. Eight papers have been selected as highly cited by ESI. The team has also filed and been granted 33 patents in China and the United States.

 They founded the biotech company "Zaiyu," which focuses on developing product pipelines such as vaccine delivery systems, transdermal drug delivery for biological macromolecules, and nano-electroporation instruments based on NEP technology. The company has completed two rounds of financing and has won multiple awards in various innovation competitions.